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Abstract
Purpose Mechanical circulatory support with a continuous-flow
left ventricular assist device (LVAD) may be a valuable treatment
in end-stage heart failure patients for an extended period of time.
The purpose of this studywas to evaluate the safety and efficacy of
implantation of a continuous-flowLVAD in end-stage heart failure
patients within the first destination program in the Netherlands.
Methods A third-generation LVAD was implanted in 16 heart
failure patients (age 61±8; 81%male; left ventricular ejection
fraction 20±6 %) as destination therapy. All patients were
ineligible for heart transplant. At baseline, 3 and 6 months,
New York Heart Association (NYHA) functional class,
quality-of-life and exercise capacity were assessed. Clinical
adverse events were registered.
Results Survival at 30 days and 6 months was 88 and 75 %,
respectively. In the postoperative phase, 6 (38 %) patients
required continuous veno-venous haemofiltration for renal fail-
ure and 2 (13 %) patients required extracorporeal membrane
oxygenation because of severe right ventricular failure. During
follow-up, NYHA functional class and quality-of-life improved
from 3.7±0.1 to 2.3±0.1 and 57±5 to 23±3 at 6 months
(P<0.001), respectively. The 6 min walking distance improved
from 168±42 m to 291±29 m at 6 months (P=0.001).
Conclusion Continuous-flow LVAD therapy is a promising
treatment for patients with end-stage heart failure ineligible for
heart transplant.
Keywords End-stage heart failure . Left ventricular assist
device . Destination therapy
Introduction
End-stage heart failure is a challenging syndrome with an
increasing incidence and prevalence worldwide. Despite ad-
vances in medical therapy and cardiac surgery, heart failure
frequently progresses and overall survival and quality-of-life
is poor [1–3]. The first-choice treatment option for end-stage
heart failure remains heart transplant [4]. However, access to
this therapy is limited due to scarcity of donor hearts.
Mechanical circulatory support with continuous-flow left ven-
tricular assist device (LVAD) is an emerging technique that
may support end-stage heart failure patients for an extended
time period and offers an alternative treatment option [5].
Traditionally, LVADs were intended as bridge to transplant,
when patients receive LVAD for a relatively short periodwhile
on the waiting list. Improvements in the design of the LVADs
led to extended duration of mechanical support and eventually
to the use of LVADs as destination therapy, when recovery
cannot be expected and transplant is not feasible [6].
Several studies have demonstrated improved survival,
functional capacity and quality-of-life in patients receiving
LVAD therapy compared with patients on optimal medical
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treatment [7–11]. However, there is still concern about the
adverse events of LVAD therapy such as infections, thrombo-
embolic events and mechanical failures [7, 8, 11]. Although
the use of LVADs has been approved as bridge to transplant in
the Netherlands, there is no experience to date with LVADs in
end-stage heart failure patients as destination therapy.
Considering the implications LVAD destination therapy may
have on the growing population of heart failure patients,
further research on this topic is needed. The purpose was to
evaluate the safety and efficacy of implantation of continuous-
flow LVAD as destination therapy in end-stage heart failure
patients who were not candidates for transplant.
Methods
Patient selection
The study population consisted of the first 16 consecutive
patients with end-stage heart failure undergoing implantation
of an LVAD as destination therapy at the Leiden University
Medical Center. By definition, all patients had New York
Heart Association (NYHA) class IIIb or IV heart failure
symptoms despite optimal medical therapy. A multi-
disciplinary cardiothoracic team determined the ineligibility
fo r gu ide l ine- recommended therapy ( inc luding
revascularisation, cardiac resynchronisation therapy and heart
failure surgery) after analysis of the patient according to the
previously described MISSION! Heart Failure protocol [12].
If patients were not considered candidates for transplant,
further screening was performed according to the MISSION!
LVAD protocol.
The MISSION! LVAD protocol comprises an extensive
screening to provide more insight into the clinical status of
the patient (Fig. 1). In particular, the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS)
level is determined, which represents a reclassification of
NYHA class IIIb-IV heart failure in order to improve selection
of patients for LVAD therapy [13]. Furthermore, quality-of-
life is determined by the Minnesota Living with Heart Failure
questionnaire, exercise capacity is assessed by a 6 min walk
test and, if feasible, maximal oxygen uptake (VO2 max) is
measured during bicycle exercise testing. An essential part of
the screening is to detect potential contraindications for long-
term LVAD support including non-cardiac morbidity limiting
life expectancy to <2 years, severe right ventricular dysfunc-
tion, active systemic infection, significant renal dysfunction
(GFR <30 ml/min) and contraindications for chronic anti-
thrombotic therapy. Also, INTERMACS level 1 was consid-
ered a contraindication for LVAD implantation since previous
studies showed an increased risk of major adverse events in
these patients [14, 15]. The decision to accept or reject patients
for LVAD implantation was made in a multi-disciplinary team
including cardiologists, thoracic surgeons, anaesthesiologists
and intensive care specialists.
LVAD implantation
All patients received a HeartWare VAD (HeartWare Inc,
Framingham, MA) [16]. Implantation of the LVAD was per-
formed according to the HeartWare instructions for use. Pump
speed was optimised peroperatively and in the intensive care
unit (ICU) using Swan-Ganz catheter measurements and
echocardiography. All patients were treated with inhaled nitric
oxide during implantation and the postoperative phase at the
ICU. After implantation, an antithrombotic regimen was ini-
tiated with heparin and clopidogrel. After haemodynamic
stabilisation, heparin was replaced by oral anticoagulation
and conventional oral heart failure medication was
re-introduced.
Follow-up
During follow-up, adverse events including death, stroke,
renal failure (defined as the need for continuous veno-
venous haemofiltration (CVVH)), severe right ventricular
failure (defined as the need for extracorporeal membrane
oxygenation (ECMO)), LVAD-related infections (driveline
exit site and pump pocket) and device failure were recorded.
The cause of death was determined by examination of the
medical reports. After hospital discharge, patients were
followed at the LVAD outpatient clinic as per protocol. At 3
and 6 months, laboratory measures, NYHA functional class
and quality-of-life were re-assessed. Exercise capacity was
determined with the 6 min walk test and with the VO2 max
uptake.
Statistical analysis
Continuous data are presented as mean ± standard deviation or
mean ± standard error of the mean, as appropriate, and cate-
gorical data are presented as frequencies and percentages.
Changes in NYHA functional class, quality-of-life score, ex-
ercise capacity and laboratory tests were evaluated using
linear mixed model analyses. A P-value <0.05 was considered
statistically significant. All data were analysed using the soft-
ware SPSS (SPSS17.0, SPSS Inc, Chicago, USA).
Results
The baseline characteristics are summarised in Table 1. Mean
age was 61±8 years and mean left ventricular ejection fraction
was 20±6 %. The main reasons for rejection for heart trans-
plant were malignancy in the medical history, severe renal
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dysfunction, and irreversible pulmonary hypertension. At
baseline, 5 (31 %) patients had NYHA class IIIb symptoms
and 11 (69 %) patients had NYHA class IV. The number of
days that patients had been hospitalised for heart failure in the
year prior to LVAD implantation was 54±55 days. According
to the INTERMACS level, 4 (25 %) patients were in level 5
Fig. 1 Flow chart of left ventricular assist device destination program
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(exercise intolerant), 3 (19 %) patients were in level 4 (recur-
rent advanced heart failure), 7 (44 %) patients were in level 3
(stable but inotrope-dependent) and 2 (13 %) patients were in
level 1 (critical cardiogenic shock). These last two patients
were in level 2 and 3 at the time of acceptance; however the
clinical situation deteriorated in the days before the operation
requiring implantation of an Impella (Abiomed, Danvers,
MA) device and an intra-aortic balloon pump, respectively.
Perioperative data
The LVAD was successfully implanted in all 16 patients. The
mean operating time was 443±146 min and mean perfusion
time was 179±66 min. The concomitant surgical procedures
performed during the LAVD implantation are displayed in
Table 2. Of particular interest is the concomitant left ventricular
aneurysmectomy in a patient with a large calcified apical
aneurysm and LVAD implantation after a previously performed
Dor reconstruction of the left ventricle [17]. Post-implantation,
patients stayed in the ICU for an average of 11±10 days and in
the cardiology ward for 31±16 days. The in-hospital mortality
was 25 %. Two patients died of cerebral haemorrhage; one
patient died from sepsis and one patient died from persistent
multi-organ failure. In the postoperative phase, 6 (38 %) pa-
tients required CVVH for kidney failure and 2 (13 %) patients
required ECMO because of severe right ventricular failure.
Three (19 %) patients underwent re-thoracotomy because of
cardiac tamponade. Two of the patients who died required
CVVH, ECMO and re-thoracotomy because of cardiac
tamponade. Patients were discharged on average 42±21 days
after LVAD implantation.
Adverse events after hospital discharge
After hospital discharge, the readmission rate for clinical
adverse events was 44 %. One patient (6 %) had an ischaemic
stroke with central facial palsy at day 61 and 2 patients (13 %)
were re-admitted for driveline infection, which was treated
successfully in both cases with antibiotics. One patient (6 %)
was re-admitted to the ICU because of acute renal failure
caused by pump thrombosis. This patient was treated success-
fully with thrombolysis, resulting in good recovery of the
LVAD and renal function. None of the patients experienced
pump failure, although 1 patient (6 %) had to exchange the
controller due to a malfunctioning plug. This controller ex-
change was successful and the patient encountered no adverse
effects.
Clinical follow-up
At 30-day and 6-month follow-up the survival rate was 88 and
75 %, respectively. The NYHA functional class significantly
improved from 3.7±0.1 at baseline to 2.6±0.2 at 3 and 2.3±
0.1 at 6 months (P<0.001). The individual data are shown in
Fig. 2. The improvement in functional class was accompanied
by an improvement in quality-of-life (Fig. 3; P<0.001). As
shown in Fig. 4, 6 min walking distance and VO2 max
improved at 6 months (P<0.05). Laboratory tests revealed
stable haemoglobin and renal function over time (Table 3).
There was a trend towards a decrease in NT-proBNP from
5578±1260 ng/l at baseline, to 3551±942 ng/l at 3 and 3230±
649 ng/l at 6 months (P=0.09).
Table 1 Baseline characteristics of patient population (n=16)
Age (years) 61±8
Male gender 13 (81 %)
BSA (m2) 2.00±0.17
NYHA functional class
IIIb 5 (31 %)
IV 11 (69 %)
INTERMACS level at the moment of surgery
1 2 (13 %)
2 -
3 7 (44 %)
4 3 (19 %)
5 4 (25 %)
LVEF (%) 20±6
Ischaemic aetiology 13 (81 %)
Cardiac index (l/min/m2) 2.18±0.43
RVSP (mmHg) 46±14
MPAP (mmHg) 32±9
Diabetes mellitus 4 (25 %)
Cardiac resynchronisation therapy 12 (75 %)
Previous thoracic surgery 9 (56 %)
Inotrope-dependent heart failure last 6 months 11 (69 %)
Intra-aortic balloon pump or Impella 2 (13 %)
No. of hospital days one year pre-implantation 54±55
BSA body surface area; LVEF left ventricular ejection fraction; MPAP
mean pulmonary artery pressure; NYHA class New York Heart Associa-
tion class; RVSP right ventricular systolic pressure
Table 2 Concomitant surgical procedure (n=16)
LV aneurysmectomy 2 (13 %)
TVannuloplasty 13 (81 %)
LAA exclusion 8 (50 %)
AVR 1 (6 %)
PFO closure 1 (6 %)
AVR aortic valve replacement; LAA left atrial appendix; PFO patent
foramen ovale; TV tricuspid valve
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Discussion
The present study evaluates the first LVAD destination pro-
gram in the Netherlands for end-stage heart failure patients.
The main findings are a 6-month survival rate of 75 % and
improvement of both functional capacity and quality-of-life during
follow-up. These results demonstrate that continuous-flow LVAD
therapy is a promising therapeutic option for patients with end-
stage heart failure ineligible for heart transplantation.
Survival
The gold standard for treatment of end-stage heart failure is heart
transplant. Survival after transplant is good with reported 1-year
survival rates of 85–90 % [18, 19]. However, due to increasing
numbers of heart failure patients and scarcity of heart donors, this
treatment is limited to a small number of patients. The introduction
of the LVAD as bridge to transplant allows better survival on
waiting lists and preservation of end-organ function. With im-
provements in the design of the LVAD, the devices have become
more durable and long-term treatment with LVADs is now
possible. Recent data demonstrated that current treatment with
LVAD results in nearly the same outcome as patients undergoing
heart transplant [5, 7, 20]. The fifth INTERMACS report showed
that actuarial 1- and 2-year survival for continuous-flow LVADS
(all indications, n=5436) is 80 and 70 %, respectively [7]. In the
current study survival at 6 months was 75 %. All patients who
died developed severe renal failure requiringCCVHand 2 patients
also developed right ventricular failure requiring ECMO. In line
with this, observed risk factors for early mortality in the
INTERMACS report were severe renal dysfunction and severe
right ventricular failure. Furthermore, INTERMACS level 1 and 2
are also associated with increased mortality after LVAD implanta-
tion [7, 14]. Two of the patients who died in the current study
deteriorated from level 2 and 3 at the time of acceptance to level
1 at the time of implantation. These events led to a change in the
protocol: a second approval moment was introduced just before
implantation. Importantly, it has been noted that patients receiving
LVAD as destination therapy carry a higher risk of death than
Fig. 2 Individual New York Heart Association (NYHA) functional class
at baseline, 3 and 6 months follow-up. Mean NYHA functional class
improved significantly from 3.7±0.1 pre-implantation to 2.6±0.2 at 3 and
2.3±0.1 at 6 months (P<0.001)
Fig. 3 Quality of life, as assessed by the Minnesota Living with
Heart Failure questionnaire, demonstrated significant improvement
at 3- and 6- month follow-up compared with baseline. Data are
presented as mean ± standard error of the mean *P<0.001 compared with
baseline
Fig. 4 Exercise capacity at baseline and at 6-month follow-up. Panel A
shows a significant increase in 6 min walking distance. Panel B shows an
improvement in peak oxygen consumption. Data are presented as
mean ± standard error of the mean
Table 3 Laboratory tests (n=16)
Baseline 3 months 6 months P
Haemoglobin (mmol/l) 7.8±0.2 7.3±0.3 7.5±0.4 0.14
eGFR (ml/min/1.73 m2) 54±5 60±5 57±5 0.22
NT-ProBNP (ng/l) 5578±1260 3551±942 3230±649 0.09
eGFR estimated glomerular filtration rate; pro-BNP N-terminal pro brain
natriuretic peptide
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bridge to transplant patients [7]. In particular, irreversible pulmo-
nary hypertension and an impaired renal function make patients
more vulnerable to postoperative complications after LVAD im-
plantation. Furthermore, additional complex surgical interventions
during implantation may complicate the operation and can affect
survival. All patients in the current studywere deemed suitable for
LVAD as destination therapy and the majority required additional
surgical interventions during implantation underlining the com-
plexity and severity of illness in the current patient group.
Adverse events
Adverse events remain of concern in the treatment of patients
with LVAD. The most commonly reported events are infec-
tions, right ventricular failure, device failure and thromboem-
bolic events [7, 8, 11, 20]. In the current study, adverse events
observed after discharge were driveline infection, pump
thrombosis, ischaemic stroke and a malfunctioning plug that
required controller exchange. Importantly, renal function and
haemoglobin levels remained stable over time and no clini-
cally relevant haemolysis was observed.
Right ventricular failure is an important cause of death in
LVAD patients and has been associated with other adverse
events such as bleeding and renal failure. The occurrence of
right ventricular failure in patients receiving LVAD therapy is
approximately 20–35 % [21, 22]. However, in the current
study only 2 patients required ECMO because of right ventric-
ular failure. These patients also developed severe renal failure.
Another concern is increased risk of infection. Although pump
pocket infections are rare, driveline infections frequently occur and
are potentially serious adverse events. The majority of infections
develop early after LVAD implantation; however, the risk remains
and increases with the duration of the LVAD use [6, 22]. In the
current study, 2 patients were re-hospitalised because of driveline
infections. Although they were treated successfully, they require
chronic antibiotic therapy. The frequency of LVAD-related infec-
tions underscores the need for special attention to driveline care
and infection prevention. Several studies have demonstrated that
the selection process influences outcome [23, 24]. However, with
the diversity in LVAD types and indications, comparison and
implementation of selection criteria remains challenging.A careful
screening program should therefore be implemented with a com-
prehensive assessment of indications and contraindications.
Functional capacity and quality-of-life
There was significant improvement in functional capacity and
quality-of-life over 6 months. At 6-month follow-up there were
no patients in NYHA class IVwhile themajority were in NYHA
class II. Patients reported that they were able to participate in
normal daily activities. This was also demonstrated by the sig-
nificant improvement in quality-of-life. In line with this, several
studies demonstrated improvement in functional capacity and
quality-of-life after LVAD implantation, despite the occurrence
of adverse events [5, 7, 11]. For instance, the Dutch study
reported by Pruijsten et al. demonstrated significant functional
and haemodynamic improvement after LVAD implantation jus-
tifying the use of an LVAD as an alternative to transplant [5].
Further improvement in the design of the LVAD may lead to a
reduction of adverse events and further improved quality-of-life.
Limitations
Our population consisted of the first patients treated with
LVAD as destination therapy in the Netherlands. This meant
we were faced with new problems that were specific for this
patient group and led to changes in our protocol. It should
therefore be noted that a learning curve was present through-
out the study. The number of patients in the current study is
small and follow-up is limited. Further research with a larger
study population and longer follow-up will be needed to
determine the safety and efficacy of LVADs as destination
therapy in end-stage heart failure patients.
Conclusion
Continuous-flow LVAD therapy is a promising therapeutic
option for patients with end-stage heart failure ineligible for
heart transplant.
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